Celgene's most recent trend suggests a bearish bias. One trading opportunity on Celgene is a Bear Call Spread using a strike $162.50 short call and a strike $167.50 long call offers a potential 16.28% return on risk over the next 9 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $162.50 by expiration. The full premium credit of $0.70 would be kept by the premium seller. The risk of $4.30 would be incurred if the stock rose above the $167.50 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Celgene is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Celgene is bearish.
The RSI indicator is at 74.04 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Celgene
Q2 comeback stocks
Thu, 12 Jun 2014 16:20:00 GMT
Valeant Pharma's Arguments About Drug Research Are Misleading And Wrong
Thu, 12 Jun 2014 15:52:00 GMT
Encouraging Long-Term Data on Celgene's Otezla
Thu, 12 Jun 2014 14:30:13 GMT
Celgene's (CELG) CEO Bob Hugin Presents at Goldman Sachs 35th Annual Global Healthcare Conference (Transcript)
Wed, 11 Jun 2014 23:31:03 GMT
Seeking Alpha – Celgene Corporation (CELG) Goldman Sachs 35th Annual Global Healthcare Conference June 8, 2014 1:00 AM ET Executives Bob Hugin – Chairman and CEO Patrick Flanigan – Vice President – Investor Relations. …
7:31 am Celgene: Oral OTEZLA Monotherapy showed long-term clinical benefits in DMARD-Na ve patients with active psoriatic arthritis
Wed, 11 Jun 2014 11:31:00 GMT
Related Posts
Also on Market Tamer…
Follow Us on Facebook